Albumin-based nanoparticles as magnetic resonance contrast agents: II. Physicochemical characterisation of purified and standardised nanoparticles

Histochemistry and Cell Biology

Volumn 134, Issue 2, 2010, Pages 171-196

  Abdelmoez, A A ^a,c   Thurner, G C ^a   Wallnofer E A ^a   Klammsteiner, N ^a   Kremser, C ^a   Talasz, H ^a   Mrakovcic, M ^b   Frohlich E ^b   Jaschke, W ^a   Debbage, P ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Center for Medical Research   (Austria)

^c Assiut University   (Egypt)

Author keywords

Albumin nanoparticles; Gadolinium; Molecular imaging; MRI; PEGylation; Targeting

Indexed keywords

ALBUMIN; ARSENAZO 3; GADOLINIUM; HUMAN SERUM ALBUMIN; NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

ARTICLE; DIAFILTRATION; DIALYSIS; HISTOCHEMISTRY; MOLECULAR IMAGING; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; SCREENING; SYNTHESIS; THIN LAYER CHROMATOGRAPHY;

CONTRAST MEDIA; DRUG DESIGN; DRUG STABILITY; HUMANS; MAGNETIC RESONANCE IMAGING; MATERIALS TESTING; NANOPARTICLES; SERUM ALBUMIN;

ANIMALIA;

EID: 78650340535     PISSN: 09486143     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00418-010-0726-6     Document Type: Article

References (70)

1. Abuchowski A, van Es T, Palczuk NC, Davis FF (1977) Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 11:3578-3581
2. Alimarin IP, Savvin SB (1966) Application of arsenazo III and other azo-compounds in the photometric determination of certain elements. Pure Appl Chem 13:445-456
3. André C, Guillaume YC (2004) Zinc-human serum albumin association: testimony of two binding sites. Talanta 63:503-508
4. Balbirnie M, Grothe R, Eisenberg DS (2001) An amyloid-forming peptide from the yeast prion Sup35 reveals a dehydrated β-sheet structure for amyloid. Proc Natl Acad Sci 98:2375-2380
5. Basargin NN, Ivanov VM, Kuznetsov VV, Mikhaliova AV (2000) 40 years since the discovery of the arsenazo III reagent. J Anal Chem 55:204-210
6. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA (2007) Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am J Roentgenol 188:586-592
7. Carter DC, Ho JX (1994) Structure of serum albumin. Adv Protein Chem 45:153-203
8. Chen RF (1967) Removal of fatty acids from serum albumin by charcoal treatment. J Biol Chem 242:173-181
9. Chick H, Martin CJ (1912) The density and solution volume of some proteins. Chem Ind Kolloide Zeitsch 11:102-107
10. Choppin GR, Schaab KM (1996) Lanthanide (III) complexation with ligands as possible contrast enhancing agents for MRI. Inorganica Chim Acta 252:299-310
11. Davidson SE, McKenzie JL, Beard MEJ, Hart DNJ (1988) The tissue distribution of the 3α-fucosyl-N-acetyl lactosamine determinant recognized by the Cd15 monoclonal antibodies Cmrf-7 and 27. Pathology 20:24-31
12. Debbage PL (1996) A systematic histochemical investigation in mammals of the dense glycocalyx glycosylations common to all cells bordering the interstitial fluid compartment of the brain. Acta Histochem 98:9-28
13. Debbage P (2009) Targeted drugs and nanomedicine: present and future. Curr Pharm Des 15:153-172
14. Debbage P, Jaschke W (2008) Molecular imaging with nanoparticles: giant roles for dwarf actors. Histochem Cell Biol 130:845-875
15. Fehske KJ, Muller WE, Wollert U (1981) The location of drug binding sites in human serum albumin. Biochem Pharmacol 30:687-692
16. Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA, Lanza GM (2001) Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 104:1280-1285
17. Foster JF, Sogami M, Peterson HA, Leonard WJ (1965) The microheterogeneity of plasma albumins. II. Preparation and solubility properties of subfractions. J Biol Chem 240:2503-2507
18. Frokjaer S, Otzen DE (2005) Protein drug stability: a formulation challenge. Nat Rev Drug Discov 4:298-306
19. Gao H, Baohua J, Jäger IL, Arzt E, Fratzl P (2003) Materials become insensitive to flaws at nanoscale: lessons from nature. Proc Nat Acad Sci USA 100:5597-5600
20. Goldschmidt L, Teng PK, Riek R, Eisenberg D (2010) Identifying the amylome, proteins capable of forming amyloid-like fibrils. Proc Natl Acad Sci 107:3487-3492
21. Goldwasser P, Feldman J (1997) Association of serum albumin and mortality risk. J Clin Epidemiol 50:693-703
22. Gonzalez ER, Kannewurf BS (1998) Clinical review of appropriate uses for albumin. US Pharm 23: HS15-HS26
23. Griffel MI, Kaufman BS (1992) Pharmacology of colloids and crystalloids. Crit Care Clin 8:235-253
24. Griffiths JR, Glickson JD (2000) Monitoring pharmacokinetics of anticancer drugs: non-invasive investigation using magnetic resonance spectroscopy. Adv Drug Deliv Rev 41:75-89
25. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348:2491-2499 (Pubitemid 36706536)
26. Hengerer A, Grimm J (2006) Molecular magnetic resonance imaging. Biomed Imaging Interv J 2: e8. doi:10.2349/biij.2.2.e8. http://www.biij.org/2006/2/e8
27. Irache JM, Durrer C, Duchene D, Ponchel G (1994) In vitro study of lectin-latex conjugates for specific bioadhesion. J Control Release 31:181-188
28. Jaffer FA, Weissleder R (2005) Molecular imaging in the clinical arena. JAMA 293:855-862
29. Karst D, Yang Y (2006) Molecular modeling study of the resistance of PLA to hydrolysis based on the blending of PLLA and PDLA. Polymer 47:4845-4850
30. Końska G, Zamorska L, Pituch-Noworolska A, Szmaciarz M, Guillot J (2003) Application of fluorescein-labelled lectins with different glycan-binding specificities to the studies of cellular glycoconjugates in human full-term placenta. Folia Histochem Cytobiol 41:155-160
31. Kragh-Hansen U (1981) Molecular aspects of ligand binding to serum albumin. Pharmacol Rev 33:17-53
32. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE (2007) Gadoliniumbased MR contrast agents and nephrogenic systemic fibrosis. Radiology 242:647-649
33. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA (2008) Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci 105:14265-14270
34. Maceke HR, Riesen A, Ritter W (1989) The molecular structure of indium-DTPA. J Nucl Med 30:1235-1239
35. Magnotti R (2008) Detection of gadolinium chelates. World Patent WO 2008/045767 A2
36. Means GE, Feeney RE (1995) Reductive alkylation of proteins. Anal Biochem 224:1-16
37. Montero EI, Benedetti BT, Mangrum JB, Oehlsen MJ, Qu Y, Farrell NP (2007) Pre-association of polynuclear platinum anticancer agents on a protein, human serum albumin. Implications for drug design. Dalton Trans 43:4938-4942
38. Mulder WJM, Strijkers GJ, van Tilborg GAF, Griffioen AW, Nicolay K (2006) Review article: lipid-based nanoparticles for contrastenhanced MRI and molecular imaging. NMR Biomed 19:142-164
39. Nagaraja TN, Croxen RL, Panda S, Knight RA, Keenan KA, Brown SL, Fenstermacher JD, Ewing JR (2006) Application of arsenazo III in the preparation and characterization of an albumin-linked, gadolinium-based macromolecular magnetic resonance contrast agent. J Neurosci Meth 157:238-245
40. Nelson R, Sawaya MR, Balbirnie M, Madsen AØ, Riekel C, Grothe R, Eisenberg D (2005) Structure of the cross-β spine of amyloidlike fibrils. Nature 435:773-778
41. Olde Damink LH, Dijkstra PJ, van Luyn MJ, van Wachem PB, Nieuwenhuis P, Feijen J (1996) In vitro degradation of dermal sheep collagen cross-linked using a water-soluble carbodiimide. Biomaterials 17:679-684 (Pubitemid 26091218)
42. Paschkunova-Martic I, Kremser C, Mistlberger K, Shcherbakova N, Dietrich H, Talasz H, Zou Y, Hugl B, Galanski M, Sölder E, Pfaller K, Höliner I, Buchberger W, Keppler B, Debbage P (2005) Design, synthesis, physical and chemical characterization, and biological interactions of lectin-targeted latex nanoparticles bearing Gd-DTPA chelates: an exploration of magnetic resonance molecular imaging (MRMI). Histochem Cell Biol 123:283-301
43. Peters T Jr (1985) Serum albumin. Adv Protein Chem 37:161-245
44. Putnam FW (1984) The Plasma Proteins, vol 4, 2nd edn. Academic Press, London
45. Rainey TG, Read CA (1994) The pharmacological approach to the critically ill patient, 3rd edn. Williams & Wilkins, Baltimore, pp 272-290
46. Rehman S, Jayson GC (2005) Molecular imaging of antiangiogenic agents. Oncol Cancer Imaging 10:92-103
47. Rinck PA (2008) Radiologists meet with heavy collateral damage. Diagnostic Imaging Europe, November 2008, pp 19-22
48. Robbens J, Vanparys C, Nobels I, Blust R, van Hoecke K, Janssen C, de Schamphelaere K, Roland K, Blanchard G, Silvestre F, Gillardin V, Kestemont P, Anthonissen R, Toussaint O, Vankoningsloo S, Saout C, Alfaro-Moreno E, Hoet P, Gonzalez L, Dubruel P, Troisfontaines P (2010) Eco-, geno-and human toxicology of bio-active nanoparticles for biomedical applications. Toxicology 296:170-181
49. Rocke AJ (2010) Image and reality: Kekulé, Kopp, and the scientific imagination. University of Chicago Press, USA, p 416
50. Rofsky NM, Sherry AD, Lenkinski RE (2008) Nephrogenic systemic fibrosis: a chemical perspective. Radiology 247:608-612
51. Rohwer H, Hosten E (1997) pH dependence of the reactions of arsenazo III with the lanthanides. Anal Chim Acta 339:271-277
52. Rowatt E, Williams RJP (1989) The interaction of cations with the dye arsenazo III. Biochem J 259:295-298
53. Rowe JD, Bobilya DJ (2000) Albumin facilitates zinc acquisition by endothelial cells. Proc Soc Exp Biol Med 224:178-186
54. Saito R, Bringas JR, McKnight TR, Wendland MF, Mamot Ch, Drummond DC, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS (2004) Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res 64:2572-2579
55. Schnabel J (2010) The dark side of proteins. Nature 464:828-829
56. Shih C (1995) Chain-end scission in acid catalyzed hydrolysis of poly (D, Llactide) in solution. J Control Release 34:9-15
57. Shrake A, Frazier D, Schwarz FP (2005) Thermal stabilization of human albumin by medium-and short-chain n-alkyl fatty acid anions. Biopolymers 81:235-248
58. Soenen SJH, Desender L, De Cuyper M (2007) Complexation of gadolinium (III) ions on top of nanometre-sized magnetoliposomes. Int J Environ Anal Chem 87:783-796
59. Spector AA (1975) Fatty acid binding to plasma albumin. J Lipid Res 16:165-179
60. Stewart AJ, Blindauer CA, Berezenko S, Sleep D, Sadler PJ (2003) Interdomain zinc site on human albumin. Proc Natl Acad Sci 100:3701-3706
61. Stollenwerk MM, Pashkunova-Martic I, Kremser C, Talasz H, Thurner GC, Abdelmoez AA, Wallnöfer EA, Helbok A, Neuhauser E, Klammsteiner N, Klimaschewski L, von Guggenberg E, Fröhlich E, Keppler B, Jaschke W, Debbage P (2010) Albumin-based nanoparticles as Magnetic Resonance contrast agents: I. Concept, first syntheses and characterisation. Histochem Cell Biol 133:375-404. doi:10.1007/s00418-010-0676-z
62. Sugio S, Kashima A, Mochizuki S, Noda M, Kobayashi K (1999) Crystal structure of human serum albumin at 2.5 Å resolution. Protein Eng 12:439-446
63. Suh WH, Suslick KS, Stucky GD, Suh YH (2009) Nanotechnology, nanotoxicology, and neuroscience. Prog Neurobiol 87:133-170
64. 15N-labeled nitroxyl radicals. Proc Natl Acad Sci 103:1463-1468 (Pubitemid 43191188)
65. Vega-Villa KR, Takemoto JK, Yáñez JA, Remsberg CM, Laird Forrest M, Davies NM (2008) Clinical toxicities of nanocarrier systems. Adv Drug Deliv Rev 60:929-938
66. Veronese FM (2001) Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 22:405-417
67. Wang J, Karihaloo BL, Duan HL (2007) Nano-mechanics or how to extend continuum mechanics to nano-scale. Bull Polish Acad Sci 55:133-140
68. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, Wickline SA (2003) Molecular imaging of angiogenesis in earlystage atherosclerosis with avβ3-integrin-targeted nanoparticles. Circulation 108:2270-2274
69. Zalipsky S (1995a) Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv Drug Deliv Rev 16:157-182
70. Zalipsky S (1995b) Functionalized poly (ethy1ene glycol) for preparation of biologically relevant conjugates. Bioconjug Chem Rev 6:150-165